Industry & Policy News

[Weill Cornell Medicine] Dr. Bishoy M. Faltas, director of bladder cancer research at the Englander Institute for Precision Medicine at Weill Cornell Medicine has been awarded a $4 million, seven-year MERIT grant from the National Cancer Institute at the National Institutes of Health.

[Nature] Siouxsie Wiles, a microbiologist at the University of Auckland, is suing her employer for failing to adequately address the harassment she received as a result of her public comments during the COVID-19 pandemic.

[Fierce Pharma] The FDA has cleared Bristol Myers’ repotrectinib, to be branded as Augtyro, to treat non-small cell lung cancer patients whose tumors have ROS1 oncogenic fusions.

[The University of Massachusetts Lowell] A UMass Lowell scientist is hoping to improve the quality of life for those with diabetes using innovative biomaterials and engineered cells and tissues, including an insulin-producing, bioengineered pancreas-like tissue.

[Fierce Pharma] Vertex and CRISPR Therapeutics have scored authorization in the UK for their exa-cel gene therapy to treat patients with severe forms of sickle cell and transfusion-dependent beta thalassemia, two genetic disorders of the blood.

[Singapore-MIT Alliance for Research and Technology (SMART)] Researchers from SMART, MIT’s research enterprise in Singapore have developed a groundbreaking technology capable of extracting MSCs directly from pure bone marrow without dilution.